News for Ping An Biomedical Co., Ltd. (NASDAQ: PASW) centers on its dual identity as an apparel supply chain management company and a business that emphasizes healthcare and biomedical technology. Company announcements describe Ping An Biomedical as a one-stop SCM service provider in the apparel industry and also as an enterprise pursuing technology-driven development in the biopharmaceutical and medical technology fields.
Recent press releases highlight strategic capital and cooperation arrangements connected to the biopharmaceutical sector. One notable item is a non-binding memorandum for a planned strategic investment in Future Biotechnology Group Co., Ltd., an enterprise focused on biopharmaceutical research and development, genetic testing, medical devices, and pharmaceutical sales. Ping An Biomedical presents this as part of its strategy to integrate biopharmaceutical R&D, clinical translation, and industrial resources.
Another key news theme is the company’s receipt of strategic investments from individual and institutional investors with backgrounds in internet platforms, venture capital, and technology-related industries. In its commentary, Ping An Biomedical links these investments to its objectives in biopharmaceutical R&D, medical technology, and the application of intelligent AI systems.
Regulatory and listing-related updates also appear in the news flow. The company has disclosed a minimum bid price deficiency notice from Nasdaq, which relates to the exchange’s continued listing requirements. Readers following PASW news can use this page to review company communications on strategic investments, capital-raising activities, and listing compliance developments as disclosed in official announcements.
Ping An Biomedical (Nasdaq: PASW) signed a letter of intent to acquire three tumor cell-related medical technology patents from Future Biotechnology Group.
The planned consideration ranges from US$2 million to US$2.5 million. The patents cover oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies. The company intends to establish an oncology and biotechnology intellectual property portfolio, with potential development through internal research, partnerships or licensing.
The transaction remains subject to due diligence, negotiation and execution of definitive agreements, and applicable regulatory and contractual requirements. Completion is not assured. The company does not expect the acquisition alone to generate material near-term revenue; it views the patents as a foundation for longer-term healthcare and biomedical initiatives.
Ping An Biomedical (PASW) approved a 1-for-40 reverse stock split of its Class A and Class B ordinary shares, effective October 23, 2026.
Class A shares are expected to begin split-adjusted trading on the Nasdaq Capital Market that day. The company expects outstanding Class A shares to move from 112,867,000 to approximately 2,821,675 and Class B shares from 12,250,000 to approximately 306,250, subject to fractional-share adjustments. Cayman Islands counsel advised that the consolidation and amended governing documents may need shareholder approval and ratification at a general meeting.
Ping An Biomedical (Nasdaq: PASW) has signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services, under which Yuan Sheng Mei Yan will act as a channel development service provider. The partners aim for cumulative sales of RMB 500 million within three years in the broader health and wellness market.
Yuan Sheng Mei Yan will use its health management platform, government-enterprise cooperation experience, and full-scenario service network to expand channels and service scenarios. Ping An Biomedical will provide biotechnology products and technical support to accelerate commercialization, enhance market penetration, and build a closed-loop from R&D to end-user consumption.
Ping An Biomedical (NASDAQ: PASW) shareholders approved all five AGM resolutions on March 18, 2026, authorizing a comprehensive capital restructure.
Key actions: authorised capital increased to US$312,500 (5,000,000,000 shares), creation of 100,000,000 Class B shares (100 votes each), targeted exchange with INSPIRETECH of 12,250,000 shares, and a conditional 1,000:1 share consolidation to occur within one year.
Ping An Biomedical (NASDAQ: PASW) signed a non-binding Investment Memorandum with Future Biotechnology Group on Jan 9, 2026 outlining an initial cash investment of US$30 million and subsequent acquisitions with aggregate consideration of US$60 million to be paid in cash and share issuances.
The Consideration Shares will be held in escrow and released subject to three annual audited revenue performance targets: RMB 750 million (2026), RMB 1.3 billion (2027), and RMB 2.3 billion (2028). Shortfalls reduce share releases; excess >50% can offset prior shortfalls. The deal targets integration of R&D, clinical translation, AI manufacturing, and commercialization to support Ping An Bio's technology-driven healthcare strategy.
Ping An Biomedical (NASDAQ: PASW) announced on January 9, 2026 that it entered into share purchase agreements with several strategic investors: Yao Jinbo (58 Group), Wang Donghui (Amiba Capital), and Li Daxue (Magcloud Group and former JD.com SVP).
The investment is described as strengthening the company’s long-term development in biopharmaceutical R&D, medical technology, and commercialization, and investors are said to bring capital, industry resources, and strategic support for technology strategy, capital planning, and ecosystem development.
Ping An Biomedical (Nasdaq: PASW) received a Nasdaq Minimum Bid Price Deficiency Letter after its closing bid price failed to meet the $1.00 minimum for the period Oct 10, 2025–Nov 20, 2025. Nasdaq provided an 180-calendar-day compliance period ending May 25, 2026 to regain compliance.
If not cured, the company may be eligible for an additional 180 days only if it meets market value and other initial listing standards (except bid price) and files intent to cure; otherwise Nasdaq may issue a delisting notice. The company is evaluating options, including a possible reverse stock split, but cannot assure successful compliance.